GA-VENTIV-TECHNOLOGY
21.7.2022 11:02:06 CEST | Business Wire | Press release
Ventiv Technology, the leading provider of risk, insurance and underwriting solutions, announced today its inclusion in the Management des Risques et des Assurances de l’Entreprise’s (AMRAE) 2022 Panorama report as leaders in Analytics and Insurance. The association’s 14th annual market analysis is based on vendor and risk manager questionnaires. Among the 55 vendors evaluated, Ventiv was one of only four to be recognized as a leader in the artificial intelligence quadrant, having both functional and technical coverage. Ventiv was one of five vendors to have that same distinction in the insurance quadrant.
According to the report, 63% of risk managers look for one tool to meet all their functional needs, audit, risk management, insurance, internal control, etc., highlighting the growing industry trend towards converging risk management systems that are cross-functional.
“Ventiv continues to grow and expand its offerings to stay on the forefront of tech and innovation,” said Steve Cloutman, Managing Director of Ventiv. “This year's report reinforces known trends and where we are headed as an industry. We look forward to continuing to be a part of moving the industry forward.”
The report also found that ease of use and reporting capabilities are the top two criteria risk managers seek when evaluating a RMIS platform. In addition, the report listed AI as one of the top three functionalities that are on the agenda for future development for most firms.
Ventiv is a differentiator when it comes to its AI-powered data analytics software. Its AI and machine learning algorithms help clients predict outcomes, prioritize time and resources, and improve operational efficiency. Combined with the company’s hands-on customer support and software offerings, clients can easily scale their risk management programs as they grow.
With more than 450 clients across Europe, North America, and Asia, Ventiv provides RMIS solutions to some of the largest global companies across a range of industries, including healthcare, manufacturing, and hospitality. This is the company’s first year being included in the report which was submitted in collaboration with EY.
The AMRAE Panorama Report is an annual publication that presents a global view of RMIS trends, market practices and details on the latest technology in the marketplace. Since 2008 AMRAE has approached the survey with a neutral point of view to provide valuable insights for risk management professionals looking for the latest info on RMIS.
Download the full report or visit Ventiv’s website for more information.
About Ventiv Technology
Ventiv Technology is a leading global provider of risk management information systems (RMIS), enterprise risk management (ERM), insurance claims, billing, policy, and administration technology integrated with its market-leading analytics and predictive models. Ventiv Technology’s SaaS and on-prem solutions are deployed by brokers, insured corporate entities, federal and regional governments, third party claims administrators (TPAs), and risk pools across a variety of industries including transportation & logistics, retail, financial services, leisure & hospitality, carriers & insurers, energy, aviation, manufacturing, government & public entities, and many more.
With over 45 years’ experience, Ventiv proudly boasts over 450 institutions as its customers and more than 350,000 users of Ventiv’s technology in over 40 countries. Ventiv’s global footprint and experienced team of industry veterans delivers insight to organizations that allows our customers to predict, manage, and respond to risk.
For more information, please visit https://www.ventivtech.com or @VentivTech .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220721005099/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom